Kadmon, the biotechnology company founded by ImClone's Sam Waksal, is preparing to file confidentially for an initial public offering, sources say.» Read More
Merck's revenues were light, but market reaction was positive. Eli Lilly's earnings were up sharply, but still disappointed the Street. So how does an investor play the results?
Stocks started the week lower, hurt by more uncertainty in the banking industry and earnings report that left investors wary after coming off a strong rally last week.
Monday has not been a great day for bank earnings. Last Monday it was Wachovia that disappointed, today futures dropped at 7 am ET as Bank of America came short of expectations.
Eli Lilly Monday posted lower-than-expected quarterly earnings, as disappointing sales of its Byetta diabetes drug overshadowed growing demand for its other medicines, sending shares 3.4 percent lower.
Stock index futures pointed to a lower start for the week as the first wave in a big week of earnings reports left investors wary.
Whenever the stock market rushes full speed ahead, it is hard not to look for the big let-down. That could be the case in the week ahead... Major earnings reports, housing data, annual shareholder meetings, and Tuesday's Pennsylvania presidential primaries are what traders will be watching to see if the trend continues.
Was Pfizer's miss, a prescription for disaster in Big Pharma? Should you sell drug makers ahead of earnings next week?
The irreverent producers of "Squawk on the Street" who are stationed in the pod next to mine here at CNBC like to call it "Pharmapalooza." They're referring to weeks like the one coming up when nearly every big drug company reports earnings.
This morning there's a plethora of stuff to blog about: the Takeda-Millennium deal, more commentary about Merck and Schering-Plough and the extent of the Vytorin/Zetia fallout, Genentech's biotech bellweather earnings after the closing bell today, just to name a few.
Pfizer and Nektar Therapeutics said Wednesday clinical trials of the inhaled insulin Exubera found increased cases of lung cancer, leading Nektar to end talks with potential partners to market the product.
Shares of Wyeth and Elan surged Monday on the promise of a new Alzheimer's drug. Can you trade it?
Last night while on the elliptical and watching "NBC Nightly News," one spot amid the wall-to-wall commercials for drugs caught my attention. It looks like after 10 years since the first erectile dysfunction pill came on the market--Pfizer's Viagra celebrated a decade since winning FDA approval last week--the makers of Levitra are trying a new marketing tack.
I don't know how I missed this one, but the Wall Street Journal's Health Blog didn't forget that this week that Pfizer and, perhaps, some men and women are celebrating the tenth birthday of Viagra. So, happy birthday little blue pill.
Ahead of the weekend, CNBC asks the experts where investors should place their bets.
The pharmaceutical sector faces the looming "patent cliff" -- but Credit Suisse's Catherine Arnold finds lots of opportunities in the sector for the careful investor.
The American College Of Cardiology kicks off its annual meeting in Chicago on Saturday. What’s the trade ahead of this major meeting of heart doctors?
As proxy statements pop up on www.sec.gov, investors can get a peek at who's making what. When you go to the web site, click on "Search for company filings," then click on "Companies and other filers," enter the ticker symbol, click on "Find companies" and then open up the "14A" or proxy statement.
Merck this morning announced that it has filed for Food and Drug Administration approval of its blockbuster cervical cancer vaccine, Gardasil, for women 27-45 years old. Right now it's approved for females 9-26.
Billionaire Alfred Mann must not have liked watching stock in the company bearing his name fall to another new low today in the wake of Eli Lilly giving up on inhaled insulin.
First, Pfizer gave up on its inhaled insulin Exubera, then NovoNordisk threw in the towel and now it looks like Lilly is going to bow out. Alkermes, which is working on a palm-sized product called, "AIR Insulin," put out a press release today saying it expects its partner on the device, Lilly, to decide next week that it will exit the deal. ALKS shares hit a new low on the news.